JP2018533959A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018533959A5 JP2018533959A5 JP2018525652A JP2018525652A JP2018533959A5 JP 2018533959 A5 JP2018533959 A5 JP 2018533959A5 JP 2018525652 A JP2018525652 A JP 2018525652A JP 2018525652 A JP2018525652 A JP 2018525652A JP 2018533959 A5 JP2018533959 A5 JP 2018533959A5
- Authority
- JP
- Japan
- Prior art keywords
- csx1
- dna
- use according
- grna
- titin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010002947 Connectin Proteins 0.000 claims description 53
- 230000005782 double-strand break Effects 0.000 claims description 53
- 108010008532 Deoxyribonuclease I Proteins 0.000 claims description 39
- 102000007260 Deoxyribonuclease I Human genes 0.000 claims description 39
- 238000000034 method Methods 0.000 claims description 38
- 210000004027 cell Anatomy 0.000 claims description 19
- 102000040430 polynucleotide Human genes 0.000 claims description 19
- 108091033319 polynucleotide Proteins 0.000 claims description 19
- 239000002157 polynucleotide Substances 0.000 claims description 19
- 108020005004 Guide RNA Proteins 0.000 claims description 18
- 102000004726 Connectin Human genes 0.000 claims description 15
- 108020004414 DNA Proteins 0.000 claims description 15
- 102000053602 DNA Human genes 0.000 claims description 15
- 229920002477 rna polymer Polymers 0.000 claims description 11
- 108091033409 CRISPR Proteins 0.000 claims description 10
- 230000035772 mutation Effects 0.000 claims description 10
- 102000004533 Endonucleases Human genes 0.000 claims description 9
- 108010042407 Endonucleases Proteins 0.000 claims description 9
- 239000002299 complementary DNA Substances 0.000 claims description 7
- 150000002632 lipids Chemical class 0.000 claims description 7
- 238000012986 modification Methods 0.000 claims description 7
- 230000004048 modification Effects 0.000 claims description 7
- 239000002105 nanoparticle Substances 0.000 claims description 7
- 230000004952 protein activity Effects 0.000 claims description 7
- 125000006850 spacer group Chemical group 0.000 claims description 7
- 230000000295 complement effect Effects 0.000 claims description 6
- 108020004999 messenger RNA Proteins 0.000 claims description 6
- 230000000747 cardiac effect Effects 0.000 claims description 5
- 239000013611 chromosomal DNA Substances 0.000 claims description 5
- 241000702421 Dependoparvovirus Species 0.000 claims description 4
- 101710163270 Nuclease Proteins 0.000 claims description 4
- 102000001708 Protein Isoforms Human genes 0.000 claims description 4
- 108010029485 Protein Isoforms Proteins 0.000 claims description 4
- 210000005260 human cell Anatomy 0.000 claims description 4
- 238000003780 insertion Methods 0.000 claims description 4
- 230000037431 insertion Effects 0.000 claims description 4
- 101150069031 CSN2 gene Proteins 0.000 claims description 3
- 208000031229 Cardiomyopathies Diseases 0.000 claims description 3
- -1 Csm2 Proteins 0.000 claims description 3
- 101150106478 GPS1 gene Proteins 0.000 claims description 3
- 101100219625 Mus musculus Casd1 gene Proteins 0.000 claims description 3
- 101100385413 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) csm-3 gene Proteins 0.000 claims description 3
- 101100047461 Rattus norvegicus Trpm8 gene Proteins 0.000 claims description 3
- 101150055766 cat gene Proteins 0.000 claims description 3
- 210000000349 chromosome Anatomy 0.000 claims description 3
- 101150055601 cops2 gene Proteins 0.000 claims description 3
- 239000002773 nucleotide Substances 0.000 claims description 3
- 125000003729 nucleotide group Chemical group 0.000 claims description 3
- 230000005783 single-strand break Effects 0.000 claims description 3
- 101150018129 CSF2 gene Proteins 0.000 claims description 2
- 101150074775 Csf1 gene Proteins 0.000 claims description 2
- 108700024394 Exon Proteins 0.000 claims description 2
- 208000021642 Muscular disease Diseases 0.000 claims description 2
- 201000009623 Myopathy Diseases 0.000 claims description 2
- 239000012634 fragment Substances 0.000 claims description 2
- 238000010362 genome editing Methods 0.000 claims description 2
- 230000001575 pathological effect Effects 0.000 claims description 2
- 238000011144 upstream manufacturing Methods 0.000 claims description 2
- 102000039446 nucleic acids Human genes 0.000 claims 13
- 108020004707 nucleic acids Proteins 0.000 claims 13
- 150000007523 nucleic acids Chemical class 0.000 claims 13
- 108091027544 Subgenomic mRNA Proteins 0.000 claims 8
- 238000003776 cleavage reaction Methods 0.000 claims 3
- 230000007017 scission Effects 0.000 claims 3
- 210000004602 germ cell Anatomy 0.000 claims 2
- 230000006780 non-homologous end joining Effects 0.000 claims 2
- 238000011084 recovery Methods 0.000 claims 2
- 108091026890 Coding region Proteins 0.000 claims 1
- 238000007385 chemical modification Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 238000010363 gene targeting Methods 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 5
- 238000001574 biopsy Methods 0.000 description 2
- 230000034431 double-strand break repair via homologous recombination Effects 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 238000005067 remediation Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021177441A JP2022009734A (ja) | 2015-11-16 | 2021-10-29 | タイチン系ミオパチー及び他のタイチノパチーの治療のための材料及び方法 |
| JP2023190737A JP2023184679A (ja) | 2015-11-16 | 2023-11-08 | タイチン系ミオパチー及び他のタイチノパチーの治療のための材料及び方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562255887P | 2015-11-16 | 2015-11-16 | |
| US62/255,887 | 2015-11-16 | ||
| PCT/US2016/062052 WO2017087395A1 (en) | 2015-11-16 | 2016-11-15 | Materials and methods for treatment of titin-based myopathies and other titinopaties |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021177441A Division JP2022009734A (ja) | 2015-11-16 | 2021-10-29 | タイチン系ミオパチー及び他のタイチノパチーの治療のための材料及び方法 |
| JP2023190737A Division JP2023184679A (ja) | 2015-11-16 | 2023-11-08 | タイチン系ミオパチー及び他のタイチノパチーの治療のための材料及び方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018533959A JP2018533959A (ja) | 2018-11-22 |
| JP2018533959A5 true JP2018533959A5 (cg-RX-API-DMAC7.html) | 2019-12-26 |
| JP7418957B2 JP7418957B2 (ja) | 2024-01-22 |
Family
ID=58717720
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018525652A Active JP7418957B2 (ja) | 2015-11-16 | 2016-11-15 | タイチン系ミオパチー及び他のタイチノパチーの治療のための材料及び方法 |
| JP2021177441A Pending JP2022009734A (ja) | 2015-11-16 | 2021-10-29 | タイチン系ミオパチー及び他のタイチノパチーの治療のための材料及び方法 |
| JP2023190737A Withdrawn JP2023184679A (ja) | 2015-11-16 | 2023-11-08 | タイチン系ミオパチー及び他のタイチノパチーの治療のための材料及び方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021177441A Pending JP2022009734A (ja) | 2015-11-16 | 2021-10-29 | タイチン系ミオパチー及び他のタイチノパチーの治療のための材料及び方法 |
| JP2023190737A Withdrawn JP2023184679A (ja) | 2015-11-16 | 2023-11-08 | タイチン系ミオパチー及び他のタイチノパチーの治療のための材料及び方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US11617783B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3377042A4 (cg-RX-API-DMAC7.html) |
| JP (3) | JP7418957B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102877920B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN108463211B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2016358172B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3005633C (cg-RX-API-DMAC7.html) |
| CO (1) | CO2018006133A2 (cg-RX-API-DMAC7.html) |
| EA (1) | EA201891192A1 (cg-RX-API-DMAC7.html) |
| HK (1) | HK1257955A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL259441B2 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2018006116A (cg-RX-API-DMAC7.html) |
| SG (1) | SG11201804166YA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2017087395A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2734621B1 (en) | 2011-07-22 | 2019-09-04 | President and Fellows of Harvard College | Evaluation and improvement of nuclease cleavage specificity |
| US9163284B2 (en) | 2013-08-09 | 2015-10-20 | President And Fellows Of Harvard College | Methods for identifying a target site of a Cas9 nuclease |
| US9359599B2 (en) | 2013-08-22 | 2016-06-07 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
| US9322037B2 (en) | 2013-09-06 | 2016-04-26 | President And Fellows Of Harvard College | Cas9-FokI fusion proteins and uses thereof |
| US9228207B2 (en) | 2013-09-06 | 2016-01-05 | President And Fellows Of Harvard College | Switchable gRNAs comprising aptamers |
| US9526784B2 (en) | 2013-09-06 | 2016-12-27 | President And Fellows Of Harvard College | Delivery system for functional nucleases |
| US9840699B2 (en) | 2013-12-12 | 2017-12-12 | President And Fellows Of Harvard College | Methods for nucleic acid editing |
| US10077453B2 (en) | 2014-07-30 | 2018-09-18 | President And Fellows Of Harvard College | CAS9 proteins including ligand-dependent inteins |
| SG10202104041PA (en) | 2015-10-23 | 2021-06-29 | Harvard College | Nucleobase editors and uses thereof |
| KR102827276B1 (ko) | 2016-08-03 | 2025-07-01 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 아데노신 핵염기 편집제 및 그의 용도 |
| WO2018031683A1 (en) | 2016-08-09 | 2018-02-15 | President And Fellows Of Harvard College | Programmable cas9-recombinase fusion proteins and uses thereof |
| WO2018039438A1 (en) | 2016-08-24 | 2018-03-01 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
| CN110214180A (zh) | 2016-10-14 | 2019-09-06 | 哈佛大学的校长及成员们 | 核碱基编辑器的aav递送 |
| US10745677B2 (en) | 2016-12-23 | 2020-08-18 | President And Fellows Of Harvard College | Editing of CCR5 receptor gene to protect against HIV infection |
| JP2020510038A (ja) | 2017-03-09 | 2020-04-02 | プレジデント アンド フェローズ オブ ハーバード カレッジ | がんワクチン |
| WO2018165504A1 (en) | 2017-03-09 | 2018-09-13 | President And Fellows Of Harvard College | Suppression of pain by gene editing |
| KR20190127797A (ko) | 2017-03-10 | 2019-11-13 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 시토신에서 구아닌으로의 염기 편집제 |
| GB2575930A (en) | 2017-03-23 | 2020-01-29 | Harvard College | Nucleobase editors comprising nucleic acid programmable DNA binding proteins |
| WO2018209320A1 (en) | 2017-05-12 | 2018-11-15 | President And Fellows Of Harvard College | Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation |
| US11732274B2 (en) | 2017-07-28 | 2023-08-22 | President And Fellows Of Harvard College | Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE) |
| EP3676376B1 (en) | 2017-08-30 | 2025-01-15 | President and Fellows of Harvard College | High efficiency base editors comprising gam |
| CA3082251A1 (en) | 2017-10-16 | 2019-04-25 | The Broad Institute, Inc. | Uses of adenosine base editors |
| EP3724214A4 (en) | 2017-12-15 | 2021-09-01 | The Broad Institute Inc. | SYSTEMS AND METHODS FOR PREDICTING REPAIR RESULTS IN GENETIC ENGINEERING |
| TWI815856B (zh) | 2018-01-31 | 2023-09-21 | 美國全美兒童醫院之研究學會 | 用於肢帶型肌肉失養症2c型之基因療法 |
| WO2019226953A1 (en) | 2018-05-23 | 2019-11-28 | The Broad Institute, Inc. | Base editors and uses thereof |
| CN112543810A (zh) * | 2018-06-29 | 2021-03-23 | 全国儿童医院研究所 | 治疗肢带型肌营养不良2a型的重组腺相关病毒产品和方法 |
| US12281338B2 (en) | 2018-10-29 | 2025-04-22 | The Broad Institute, Inc. | Nucleobase editors comprising GeoCas9 and uses thereof |
| US12351837B2 (en) | 2019-01-23 | 2025-07-08 | The Broad Institute, Inc. | Supernegatively charged proteins and uses thereof |
| BR112021016570A2 (pt) | 2019-02-26 | 2021-11-03 | Res Inst Nationwide Childrens Hospital | Entrega de vetor de vírus adenoassociado de beta-sarcoglicano e tratamento de distrofia muscular |
| DE112020001306T5 (de) | 2019-03-19 | 2022-01-27 | Massachusetts Institute Of Technology | Verfahren und zusammensetzungen zur editierung von nukleotidsequenzen |
| US12473543B2 (en) | 2019-04-17 | 2025-11-18 | The Broad Institute, Inc. | Adenine base editors with reduced off-target effects |
| EP4374880A3 (en) | 2019-08-21 | 2024-08-14 | Research Institute at Nationwide Children's Hospital | Adeno-associated virus vector delivery of alpha-sarcoglycan and the treatment of muscular dystrophy |
| US12435330B2 (en) | 2019-10-10 | 2025-10-07 | The Broad Institute, Inc. | Methods and compositions for prime editing RNA |
| AU2021267940A1 (en) | 2020-05-08 | 2022-12-08 | President And Fellows Of Harvard College | Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence |
| CA3207527A1 (en) | 2021-02-05 | 2022-08-11 | Eric B. Kmiec | Methods of and compositions for reducing gene expression and/or activity |
| CN113512536A (zh) * | 2021-05-07 | 2021-10-19 | 山东大学深圳研究院 | 一种用于制备人体多巴胺神经元的试剂盒及其应用 |
| US12285497B2 (en) | 2021-10-15 | 2025-04-29 | Research Institute At Nationwide Children's Hospital | Self-complementary adeno-associated virus vector and its use in treatment of muscular dystrophy |
| WO2023190935A1 (en) * | 2022-03-31 | 2023-10-05 | Modalis Therapeutics Corporation | Method for treating myopathies by targeting titin gene |
| CN120435556A (zh) * | 2022-04-25 | 2025-08-05 | 杰克森实验室 | 用于治疗扩张型心肌病的方法及其药物组合物 |
Family Cites Families (107)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE58011B1 (en) | 1983-05-27 | 1993-06-16 | Texas A & M Univ Sys | Method for producing a recombinant baculovirus expression vector |
| ZA848495B (en) | 1984-01-31 | 1985-09-25 | Idaho Res Found | Production of polypeptides in insect cells |
| US5449616A (en) | 1990-05-23 | 1995-09-12 | University Of Iowa Research Foundation | Nucleic acid encoding dystrophin-associated protein |
| US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
| WO1995003392A1 (en) | 1993-07-23 | 1995-02-02 | Unichema Chemie Bv | Process for producing transparent soap material |
| ES2216005T3 (es) | 1993-11-09 | 2004-10-16 | Targeted Genetics Corporation | Produccion de titulos elevados de vectores de aav recombinantes. |
| CA2176215C (en) | 1993-11-09 | 2007-06-26 | James P. Trempe | Stable cell lines capable of expressing the adeno-associated virus replication gene |
| US5658785A (en) | 1994-06-06 | 1997-08-19 | Children's Hospital, Inc. | Adeno-associated virus materials and methods |
| US6204059B1 (en) | 1994-06-30 | 2001-03-20 | University Of Pittsburgh | AAV capsid vehicles for molecular transfer |
| US5856152A (en) | 1994-10-28 | 1999-01-05 | The Trustees Of The University Of Pennsylvania | Hybrid adenovirus-AAV vector and methods of use therefor |
| EP0796339A1 (en) | 1994-12-06 | 1997-09-24 | Targeted Genetics Corporation | Packaging cell lines for generation of high titers of recombinant aav vectors |
| FR2737730B1 (fr) | 1995-08-10 | 1997-09-05 | Pasteur Merieux Serums Vacc | Procede de purification de virus par chromatographie |
| CA2625279A1 (en) | 1995-08-30 | 1997-03-06 | Genzyme Corporation | Chromatographic purification of adenovirus and aav |
| AU715543B2 (en) | 1995-09-08 | 2000-02-03 | Genzyme Corporation | Improved AAV vectors for gene therapy |
| US5672694A (en) | 1995-10-24 | 1997-09-30 | University Of Iowa Research Foundation | β-sarcoglycan nucleic acid sequence, and nucleic acid probes |
| US5910434A (en) | 1995-12-15 | 1999-06-08 | Systemix, Inc. | Method for obtaining retroviral packaging cell lines producing high transducing efficiency retroviral supernatant |
| ATE465267T1 (de) | 1996-09-06 | 2010-05-15 | Univ Pennsylvania | Rekombinante aav zur herstellung eines medikaments für die gentherapie von muskelzellen |
| AU758708B2 (en) | 1997-09-05 | 2003-03-27 | Targeted Genetics Corporation | Methods for generating high titer helper-free preparations of recombinant AAV vectors |
| US6566118B1 (en) | 1997-09-05 | 2003-05-20 | Targeted Genetics Corporation | Methods for generating high titer helper-free preparations of released recombinant AAV vectors |
| WO1999043360A1 (en) | 1998-02-26 | 1999-09-02 | The Trustees Of The University Of Pennsylvania | Stable protection from dystrophic sarcolemmal degeneration and restoration of the sarcoglycan complex |
| US6262035B1 (en) | 1998-10-01 | 2001-07-17 | University Of Iowa Research Foundation | Gene replacement therapy for muscular dystrophy |
| US6258595B1 (en) | 1999-03-18 | 2001-07-10 | The Trustees Of The University Of Pennsylvania | Compositions and methods for helper-free production of recombinant adeno-associated viruses |
| US6632800B1 (en) | 1999-08-17 | 2003-10-14 | Mayo Foundation For Medical Education And Research | System for monitoring the expression of transgenes |
| JP4520569B2 (ja) | 2000-02-18 | 2010-08-04 | 照彦 豊岡 | 拡張型心筋症の遺伝子治療剤 |
| WO2001083692A2 (en) | 2000-04-28 | 2001-11-08 | The Trustees Of The University Of Pennsylvania | Recombinant aav vectors with aav5 capsids and aav5 vectors pseudotyped in heterologous capsids |
| AU2002248297A1 (en) | 2001-01-05 | 2002-07-16 | Children's Hospital, Inc. | Aav2 vectors and methods |
| WO2003015615A2 (en) | 2001-08-15 | 2003-02-27 | Brown University Research Foundation | Treatment of muscular dystrophies and related disorders |
| US20040126762A1 (en) | 2002-12-17 | 2004-07-01 | Morris David W. | Novel compositions and methods in cancer |
| EP2359869B1 (en) | 2001-12-17 | 2018-12-26 | The Trustees Of The University Of Pennsylvania | Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same and uses therefor |
| AU2003212708A1 (en) | 2002-03-05 | 2003-09-16 | Stichting Voor De Technische Wetenschappen | Baculovirus expression system |
| WO2003092594A2 (en) | 2002-04-30 | 2003-11-13 | Duke University | Adeno-associated viral vectors and methods for their production from hybrid adenovirus and for their use |
| US20030225260A1 (en) | 2002-04-30 | 2003-12-04 | Snyder Richard O. | Production of recombinant AAV virions |
| BRPI0511764B8 (pt) | 2004-06-01 | 2021-05-25 | Avigen Inc | método de prevenção de agregação de vírions de vírus adeno-associado recombinante (raav) em uma preparação purificada de virions raav |
| US7972593B2 (en) | 2004-06-10 | 2011-07-05 | Saint Louis University | Delivery of therapeutic agents to the bone |
| WO2006039218A2 (en) | 2004-09-30 | 2006-04-13 | The Trustees Of The University Of Pennsylvania | Perfusion circuit and use therein in targeted delivery of macromolecules |
| JP2006121961A (ja) | 2004-10-28 | 2006-05-18 | Univ Of Tokushima | 顎骨骨幹異形成症ｇｄｄの原因遺伝子ｇｄｄ１とその用途 |
| US7883858B2 (en) | 2005-01-27 | 2011-02-08 | Institute For Systems Biology | Methods for identifying and monitoring drug side effects |
| US7788045B2 (en) | 2005-09-01 | 2010-08-31 | Meditasks, Llc | Systems and method for homeostatic blood states |
| EP1938104A2 (en) | 2005-10-17 | 2008-07-02 | Institute for Systems Biology | Tissue-and serum-derived glycoproteins and methods of their use |
| WO2007049095A1 (en) | 2005-10-25 | 2007-05-03 | Cellectis | Laglidadg homing endonuclease variants having mutations in two functional subdomains and use thereof |
| US9198984B2 (en) | 2006-04-28 | 2015-12-01 | The Trustees Of The University Of Pennsylvania | Scalable production method for AAV |
| WO2008016356A2 (en) | 2006-08-02 | 2008-02-07 | Genizon Biosciences | Genemap of the human genes associated with psoriasis |
| WO2008021290A2 (en) | 2006-08-09 | 2008-02-21 | Homestead Clinical Corporation | Organ-specific proteins and methods of their use |
| US20100093089A1 (en) * | 2006-11-09 | 2010-04-15 | Eduardo Marban | Dedifferentiation of adult mammalian cardiomyocytes into cardiac stem cells |
| WO2008088895A2 (en) | 2007-01-18 | 2008-07-24 | University Of Missouri-Columbia | Synthetic mini/micro-dystrophin genes to restore nnos to the sarcolemma |
| FR2919305B1 (fr) | 2007-07-26 | 2009-09-18 | Genethon Ass Loi De 1901 | Vecteurs viraux adeno-associes pour l'expression de la dysferline. |
| GB0715087D0 (en) | 2007-08-03 | 2007-09-12 | Summit Corp Plc | Drug combinations for the treatment of duchenne muscular dystrophy |
| ES2564563T3 (es) | 2007-10-26 | 2016-03-23 | Academisch Ziekenhuis Leiden | Medios y métodos para contrarrestar trastornos del músculo |
| US8236527B2 (en) | 2008-03-14 | 2012-08-07 | Humanzyme Limited | Recombinant production of authentic human proteins using human cell expression systems |
| US20090280103A1 (en) | 2008-04-04 | 2009-11-12 | Martin Flueck | Regulation of muscle repair |
| WO2009137006A2 (en) | 2008-04-30 | 2009-11-12 | The University Of North Carolina At Chapel Hill | Directed evolution and in vivo panning of virus vectors |
| US8236557B2 (en) | 2008-05-28 | 2012-08-07 | University Of Missouri-Columbia | Hybrid-AAV vectors to deliver large gene expression cassette |
| US20100026655A1 (en) | 2008-07-31 | 2010-02-04 | Avago Technologies Ecbu Ip (Singapore) Pte. Ltd. | Capacitive Touchscreen or Touchpad for Finger or Stylus |
| WO2010065630A2 (en) | 2008-12-03 | 2010-06-10 | The Johns Hopkins University | Compositions and methods for treating hepatic neoplasia |
| US20110023139A1 (en) * | 2008-12-04 | 2011-01-27 | Sigma-Aldrich Co. | Genomic editing of genes involved in cardiovascular disease |
| US20100247495A1 (en) | 2009-03-30 | 2010-09-30 | Tom Ichim | Treatment of Muscular Dystrophy |
| US8946451B2 (en) | 2009-10-05 | 2015-02-03 | Catabasis Pharmaceuticals, Inc. | Lipoic acid acylated salicylate derivatives and their uses |
| KR20120099709A (ko) | 2009-11-03 | 2012-09-11 | 더 리전츠 오브 더 유니버시티 오브 캘리포니아 | 하나 이상의 표면 위의 아연 산화물 나노로드 어레이들을 이용하는 발광 다이오드 구조물 및 이러한 아연 산화물 나노로드 어레이들을 저비용으로 제조하는 방법 |
| FR2962041B1 (fr) | 2010-07-01 | 2012-07-27 | Genethon | Inhibiteurs de la calpaine 3 pour le traitement de dystrophies musculaires et de cardiomyopathies |
| EP4488370A2 (en) | 2011-07-25 | 2025-01-08 | Nationwide Children's Hospital, Inc. | Recombinant virus products and methods for inhibition of expresssion of dux4 |
| WO2013075008A1 (en) | 2011-11-16 | 2013-05-23 | University Of Florida Research Foundation Inc. | Aav dual vector systems for gene therapy |
| WO2013078316A1 (en) | 2011-11-23 | 2013-05-30 | Nationwide Children's Hospital, Inc. | Recombinant adeno-associated virus delivery of alpha-sarcoglycan polynucleotides |
| AU2013221212B2 (en) | 2012-02-17 | 2018-08-09 | The Children's Hospital Of Philadelphia | AAV vector compositions and methods for gene transfer to cells, organs and tissues |
| EP2834260A4 (en) | 2012-04-02 | 2016-08-10 | Moderna Therapeutics Inc | MODIFIED POLYNUCLEOTIDES FOR THE PREPARATION OF MEMBRANE PROTEINS |
| US10501512B2 (en) | 2012-04-02 | 2019-12-10 | Modernatx, Inc. | Modified polynucleotides |
| WO2013176772A1 (en) | 2012-05-25 | 2013-11-28 | The Regents Of The University Of California | Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription |
| RS61985B1 (sr) | 2012-09-06 | 2021-07-30 | Univ Chicago | Antisens polinukleotidi za indukovanje preskakanja egzona i postupci lečenja distrofija |
| WO2014037526A1 (en) | 2012-09-07 | 2014-03-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | In vitro genetic diagnostic of inherited neuromuscular disorders |
| MX369519B (es) * | 2012-09-25 | 2019-11-11 | Genzyme Corp | Oligonucleotidos antisentido morfolino unidos a peptido para el tratamiento de distrofia miotonica. |
| US9624282B2 (en) | 2012-11-26 | 2017-04-18 | The Curators Of The University Of Missouri | Microdystrophin peptides and methods for treating muscular dystrophy using the same |
| SG10201707569YA (en) | 2012-12-12 | 2017-10-30 | Broad Inst Inc | Delivery, Engineering and Optimization of Systems, Methods and Compositions for Sequence Manipulation and Therapeutic Applications |
| PL2771468T3 (pl) | 2012-12-12 | 2015-07-31 | Broad Inst Inc | Inżynieria systemów, metod i zoptymalizowanych kompozycji kierujących dla manipulacji sekwencjami |
| EP2840140B2 (en) | 2012-12-12 | 2023-02-22 | The Broad Institute, Inc. | Crispr-Cas based method for mutation of prokaryotic cells |
| FR3004463A1 (fr) | 2013-04-11 | 2014-10-17 | Genethon | Systeme d'expression pour une therapie genique selective |
| WO2014204725A1 (en) | 2013-06-17 | 2014-12-24 | The Broad Institute Inc. | Optimized crispr-cas double nickase systems, methods and compositions for sequence manipulation |
| ITTO20130669A1 (it) | 2013-08-05 | 2015-02-06 | Consiglio Nazionale Ricerche | Vettore adeno-associato ricombinante muscolo-specifico e suo impiego nel trattamento di patologie muscolari |
| TW201536329A (zh) | 2013-08-09 | 2015-10-01 | Isis Pharmaceuticals Inc | 用於調節失養性肌強直蛋白質激酶(dmpk)表現之化合物及方法 |
| ES2666322T3 (es) | 2013-10-08 | 2018-05-04 | Ystem S.R.L. | Composiciones farmacéuticas para el tratamiento de trastornos musculares |
| US9850497B2 (en) * | 2013-11-04 | 2017-12-26 | Regents Of The University Of Minnesota | Gene targeting methods and tools |
| CN106536729A (zh) * | 2013-12-12 | 2017-03-22 | 布罗德研究所有限公司 | 使用粒子递送组分靶向障碍和疾病的crispr‑cas系统和组合物的递送、用途和治疗应用 |
| EP3800261A1 (en) | 2014-01-21 | 2021-04-07 | Vrije Universiteit Brussel | Muscle-specific nucleic acid regulatory elements and methods and use thereof |
| DE102014207498A1 (de) | 2014-04-17 | 2015-10-22 | Universitätsklinikum Hamburg-Eppendorf | Viraler Vektor für den zielgerichteten Gentransfer in Gehirn und Rückenmark |
| EP2960336A1 (en) | 2014-06-27 | 2015-12-30 | Genethon | Efficient systemic treatment of dystrophic muscle pathologies |
| JP6832280B2 (ja) | 2015-01-16 | 2021-02-24 | ユニバーシティ オブ ワシントンＵｎｉｖｅｒｓｉｔｙ ｏｆ Ｗａｓｈｉｎｇｔｏｎ | 新規のマイクロジストロフィンおよび使用の関連する方法 |
| WO2017165859A1 (en) | 2016-03-24 | 2017-09-28 | Research Institute At Nationwide Children's Hospital | Modified viral capsid proteins |
| RS65490B1 (sr) | 2016-04-15 | 2024-05-31 | Res Inst Nationwide Childrens Hospital | Vektor adeno-asociranog virusa za isporuku β-sarkoglikana i mikrorna-29 i tretman mišićne distrofije |
| MX2018012537A (es) | 2016-04-15 | 2019-02-25 | Univ Pennsylvania | Terapia de genes para tratar hemofilia a. |
| MA45477A (fr) | 2016-04-15 | 2019-02-20 | Res Inst Nationwide Childrens Hospital | Administration à vecteurs de virus adéno-associé de microarn-29 et micro-dystrophine pour traiter la dystrophie musculaire |
| CA2971303A1 (en) | 2016-06-21 | 2017-12-21 | Bamboo Therapeutics, Inc. | Optimized mini-dystrophin genes and expression cassettes and their use |
| JP7162021B2 (ja) | 2017-03-17 | 2022-10-27 | ニューカッスル ユニバーシティ | 筋ジストロフィーを治療するためのマイクロジストロフィン断片のアデノ随伴ウイルスベクター送達 |
| ES2948233T3 (es) | 2017-03-17 | 2023-09-06 | Res Inst Nationwide Childrens Hospital | Administración mediante vector de virus adenoasociado de microdistrofina específica de músculo para tratar la distrofia muscular |
| MA50836A (fr) | 2017-10-18 | 2020-08-26 | Res Inst Nationwide Childrens Hospital | Administration par vecteur à virus adéno-associé de micro-dystrophine spécifique de muscles pour traiter la dystrophie musculaire |
| MY207563A (en) | 2017-10-20 | 2025-03-04 | Res Inst Nationwide Childrens Hospital | Methods and materials for nt-3 gene therapy |
| WO2019118806A1 (en) | 2017-12-14 | 2019-06-20 | Solid Biosciences Inc. | Non-viral production and delivery of genes |
| TWI815856B (zh) | 2018-01-31 | 2023-09-21 | 美國全美兒童醫院之研究學會 | 用於肢帶型肌肉失養症2c型之基因療法 |
| US20210139550A1 (en) | 2018-04-03 | 2021-05-13 | Curators Of The University Of Missouri | Hinges 1 and/or 4 modified dystrophins for dystrophinopathy therapy |
| WO2019209777A1 (en) | 2018-04-23 | 2019-10-31 | The Curators Of The University Of Missouri | Improved crispr therapy |
| PT3807413T (pt) | 2018-06-18 | 2025-08-19 | Res Inst Nationwide Childrens Hospital | Administração por vetor de vírus adenoassociado de microdistrofina específica do músculo para tratar a distrofia muscular |
| CN112543810A (zh) | 2018-06-29 | 2021-03-23 | 全国儿童医院研究所 | 治疗肢带型肌营养不良2a型的重组腺相关病毒产品和方法 |
| CN113646004A (zh) | 2018-12-12 | 2021-11-12 | 坚固生物科技公司 | 用于治疗肌营养不良的组合疗法 |
| BR112021016570A2 (pt) | 2019-02-26 | 2021-11-03 | Res Inst Nationwide Childrens Hospital | Entrega de vetor de vírus adenoassociado de beta-sarcoglicano e tratamento de distrofia muscular |
| EP4374880A3 (en) | 2019-08-21 | 2024-08-14 | Research Institute at Nationwide Children's Hospital | Adeno-associated virus vector delivery of alpha-sarcoglycan and the treatment of muscular dystrophy |
| US20230040544A1 (en) | 2019-12-16 | 2023-02-09 | Research Institute At Nationwide Children's Hospital | Compositions and methods for restoring and maintaining the dystrophin-associated protein complex (dapc) |
| WO2021257595A1 (en) | 2020-06-15 | 2021-12-23 | Research Institute At Nationwide Children's Hospital | Adeno-associated virus vector delivery for muscular dystrophies |
| JP2023534127A (ja) | 2020-06-17 | 2023-08-08 | アクセルロン ファーマ インコーポレイテッド | ＡｃｔＲＩＩ－ＡＬＫ４アンタゴニストおよび心不全を処置する方法 |
| TWI887479B (zh) | 2020-09-08 | 2025-06-21 | 美商薩羅塔治療公司 | 表現γ-肌聚醣之腺相關病毒載體之全身性遞送及肌肉失養症之治療 |
| US20230390417A1 (en) | 2022-06-02 | 2023-12-07 | Research Institute At Nationwide Children's Hospital | Recombinant Adeno-Associated Virus Products and Methods for Treating Limb Girdle Muscular Dystrophy 2A |
-
2016
- 2016-11-15 EP EP16866951.3A patent/EP3377042A4/en active Pending
- 2016-11-15 MX MX2018006116A patent/MX2018006116A/es unknown
- 2016-11-15 CN CN201680078207.8A patent/CN108463211B/zh active Active
- 2016-11-15 IL IL259441A patent/IL259441B2/en unknown
- 2016-11-15 WO PCT/US2016/062052 patent/WO2017087395A1/en not_active Ceased
- 2016-11-15 KR KR1020187016954A patent/KR102877920B1/ko active Active
- 2016-11-15 JP JP2018525652A patent/JP7418957B2/ja active Active
- 2016-11-15 HK HK19100317.5A patent/HK1257955A1/zh unknown
- 2016-11-15 EA EA201891192A patent/EA201891192A1/ru unknown
- 2016-11-15 SG SG11201804166YA patent/SG11201804166YA/en unknown
- 2016-11-15 CA CA3005633A patent/CA3005633C/en active Active
- 2016-11-15 US US15/776,714 patent/US11617783B2/en active Active
- 2016-11-15 AU AU2016358172A patent/AU2016358172B2/en active Active
-
2018
- 2018-06-15 CO CONC2018/0006133A patent/CO2018006133A2/es unknown
-
2021
- 2021-10-29 JP JP2021177441A patent/JP2022009734A/ja active Pending
-
2023
- 2023-02-01 US US18/162,850 patent/US12472239B2/en active Active
- 2023-11-08 JP JP2023190737A patent/JP2023184679A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018533959A5 (cg-RX-API-DMAC7.html) | ||
| JP2022009734A (ja) | タイチン系ミオパチー及び他のタイチノパチーの治療のための材料及び方法 | |
| JP6997623B2 (ja) | オリゴヌクレオチドを利用して細胞内の核酸を編集するための組成物および方法 | |
| EP3359677B1 (en) | Compositions and methods for treating fragile x syndrome and related syndromes | |
| CA3177380A1 (en) | Compositions and methods for modifying target rnas | |
| WO2017004616A1 (en) | Crispr/cas9-based treatments | |
| JP2019507579A5 (cg-RX-API-DMAC7.html) | ||
| JP2021521889A (ja) | 脊髄性筋萎縮症を処置するための組成物および方法 | |
| Zhang et al. | Gene therapy for monogenic disorders: challenges, strategies, and perspectives | |
| CN112662674B (zh) | 靶向编辑VEGFA基因外显子区域的gRNA及其应用 | |
| JP2025121988A (ja) | 効率的なｒｎａトランススプライシングのための三重らせんターミネータ | |
| Eslahi et al. | New advancements in CRISPR based gene therapy of Duchenne muscular dystrophy | |
| JP2025509392A (ja) | 改変型ｃｒｉｓｐｒベースの遺伝子編集システムおよび使用方法 | |
| EP4610355A1 (en) | Gene editing system and use thereof | |
| EP3868887A1 (en) | Novel virus vector and methods for producing and using same | |
| US20250207115A1 (en) | Engineered crispr-cas13f system and uses thereof | |
| CN118581064A (zh) | 核酸修饰酶、包含其的碱基编辑器及其应用 | |
| CN116004641A (zh) | 一种构建Lrp5 A241T基因点突变高骨量小鼠模型的方法 | |
| CN116334141A (zh) | 基于基因编辑的RHO-R135W-adRP基因编辑药物 | |
| WO2021212686A1 (zh) | RHO-adRP基于基因编辑的方法和组合物 | |
| CN118086297B (zh) | 用于人HAO1基因编辑的sgRNA、组合物及其应用 | |
| Jo et al. | Employing nonhomologous end joining and homology-directed repair for treatment of Leber congenital amaurosis and inherited retinal degeneration | |
| Baruah et al. | Macular Corneal Dystrophy: Past | |
| Kamiya et al. | Targeted sequence alteration of a chromosomal locus in mouse liver | |
| KR20190037167A (ko) | 혈액응고인자 viii 유전자 역위 보정능의 유전자 가위 시스템으로 구성된 혈우병 치료용 조성물 |